RNA vaccine trial offers new hope for kids with Hard-to-Treat cancers
NCT ID NCT05660408
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests a new RNA vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma (a brain cancer) or osteosarcoma (a bone cancer). The vaccine aims to train the body's immune system to attack cancer cells. The trial will check safety, the right dose, and whether the vaccine activates immune cells. It is not a cure, but a way to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HIGH-GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UF Health
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.